Literature DB >> 3264498

Appearance of hybridoma growth factor/interleukin-6 in the serum of mice bearing a methylcholanthrene-induced sarcoma.

J Gelin1, L L Moldawer, C Lonnroth, P deMan, C Svanborg-Eden, S F Lowry, K G Lundholm.   

Abstract

Serum concentrations of hybridoma growth factor/interleukin-6 progressively increased in mice bearing a transplantable methylcholanthrene-induced sarcoma with tumor growth. Elevated HGF/interleukin-6 concentrations were also positively correlated with increased serum concentrations of the hepatic acute phase reactant protein, amyloid P. Daily Indomethacin treatment of sarcoma-bearing mice prolonged survival and reduced the magnitude of the serum amyloid P response, but failed to attenuate either tumor growth or serum HGF/interleukin-6 responses. Since previous studies have demonstrated that neither interleukin-1 nor tumor necrosis factor-alpha can be detected in the serum of these sarcoma-bearing mice, and that HGF/interleukin-6 is a principal mediator of the hepatic acute phase response, we conclude that circulating HGF/interleukin-6 may contribute significantly to the host responses which accompany experimentally-introduced cancer. Furthermore, prostanoid inhibition does not appear to regulate the synthesis and release of HGF/interleukin-6 during tumor growth.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3264498     DOI: 10.1016/s0006-291x(88)80288-2

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

Review 1.  IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation.

Authors:  B E Barton
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Interleukin-6 immunoreactivity in human tumors.

Authors:  S S Tabibzadeh; D Poubouridis; L T May; P B Sehgal
Journal:  Am J Pathol       Date:  1989-09       Impact factor: 4.307

3.  Interactions between rnacrophage cytokines and eicosanoids in expression of antitumour activity.

Authors:  S Ben-Efraim
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.